Fig. 7: p-AKT expression correlates with PFS in ER+ metastatic breast cancer patients treated with combined CDK4/6i and endocrine therapy. | Nature Communications

Fig. 7: p-AKT expression correlates with PFS in ER+ metastatic breast cancer patients treated with combined CDK4/6i and endocrine therapy.

From: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Fig. 7

A Kaplan-Meier plots evaluating progression-free survival (PFS) according to p-AKT (S473) levels in ER+ metastatic lesions from a validation cohort of ER+breast cancer patients treated with combined CDK4/6i and endocrine therapy in the advanced setting. A two-sided p-value (p < 0.05) was calculated using log-rank testing. Representative micrographs of all breast cancer metastasis sections showing low p-AKT expression (H-score < 150, B and C) or high p-AKT expression (H-score ≥ 150, D and E; scale bars, 100 µm).

Back to article page